Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression Post author:Sam Post published:November 8, 2017 Post category:BioPharma The positive results support the company’s planned regulatory submissions. Source: BioSpace You Might Also Like 22nd Century Group, Inc. Now Free Of Restrictive License Agreement With September 24, 2017 Troubled Dimension Therapeutics Sold in All-Stock Deal August 24, 2017 DxTerity Collaborates With On The Development Of A Cancer Genomic Blood Test To Predict Response To Radiation Therapy September 21, 2017
DxTerity Collaborates With On The Development Of A Cancer Genomic Blood Test To Predict Response To Radiation Therapy September 21, 2017
